By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


REGENX Biosciences, LLC 

750 17th St. NW, Suite 1100

Washington  D.C.   20006  U.S.A.
Phone: 202-785-7438 Fax:


Company News
ABL, Inc. Announces Agreements With REGENXBIO For Process Development, Scale-Up And Clinical Manufacturing Of RGX-501 5/24/2016 8:23:40 AM
Biogen (BIIB) Aligns with Two Super Stars and Bags a Deal with REGENXBIO in Gene Therapy Push 5/16/2016 6:42:22 AM
Booming REGENXBIO Expands from 5 to 60 Employees on Strength of Gene Therapy Licenses 3/2/2016 6:40:42 AM
REGENXBIO To Participate In Upcoming Investor And Scientific Conferences 12/1/2015 7:57:33 AM
REGENXBIO Reports Third Quarter 2015 Results 11/5/2015 10:18:49 AM
Dr. David C. Stump Appointed To REGENXBIO Board Of Directors 10/15/2015 7:43:39 AM
FDA Grants Orphan Drug Designation To REGENXBIO's RGX-111 Gene Therapy For The Treatment Of Mucopolysaccharidosis Type I (MPS I) 10/2/2015 7:45:03 AM
REGENXBIO Announces Closing Of Initial Public Offering And Full Exercise Of Underwriters' Option To Purchase Additional Shares 9/23/2015 7:20:08 AM
REGENXBIO Takes Center Stage With $139M IPO 9/17/2015 5:54:49 AM
Gene Therapy Biotech REGENXBIO Increases Proposed IPO Price To $22 9/16/2015 11:52:13 AM